Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27242624 | 0.74 | SMN1; SMN2 (0.37) | ARLMNASMN1; SMN2CA12CA9 | |
| SCHEMBL19152469 | 0.74 | NOS1 (0.39) | NOS1ARLMNACA12CA9 | |
| SCHEMBL13454727 | 0.74 | PDE3B (0.42) | ARKDM4ECYP1A2MEN1GAA | |
| SCHEMBL13724990 | 0.74 | CYP3A4 (0.38) | LMNASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL15650551 | 0.71 | ENPP3 (0.41) | BACE1ARSMN1; SMN2PDPK1MAPT | |
| SCHEMBL22559200 | 0.71 | CYP1A2 (0.39) | LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24873580 | 0.71 | HTR2A (0.31) | — | |
| SCHEMBL18003573 | 0.71 | KEAP1 (0.52) | LMNASMN1; SMN2CA12CA9NPC1 | |
| SCHEMBL5201632 | 0.70 | ALDH1A1 (0.46) | SMN1; SMN2NPC1RAB9AKDM4ECYP1A2 | |
| SCHEMBL21672119 | 0.69 | CA2 (0.39) | CYP3A4MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12221442-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240246962-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11926626-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-114907387-B | Pyrimido pyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023185811-A1 | NOVEL HETEROCYCLIC COMPOUND | 首药控股(北京)股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| CN-100584830-C | Gabanergic modulators | HOFFMANN LA ROCHE LLC | 2010-01-27 | — | — | CN | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| CN-1852897-A | Gamma-aminobutyric acid modulators | ROCHE PALO ALTO LLC (CH) | 2006-10-25 | — | — | CN | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246962-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | BACE1 1029/4885NOS1 3183/4885AR 657/4885 |
| US-12221442-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | BACE1 1029/4885NOS1 3183/4885AR 657/4885 |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | BACE1 1029/4885NOS1 3183/4885AR 657/4885 |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | BACE1 576/4885NOS1 3717/4885AR 4160/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | BACE1 1312/4885NOS1 3675/4885AR 1962/4885 |
| US-11926626-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | BACE1 1029/4885NOS1 3183/4885AR 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.